JPRN-jRCT2080224759招募中1 期
A phase Ia/Ib, open label, dose-escalation study of the combination of BI 907828 with BI 754091 (ezabenlimab) and BI 754111 and the combination of BI 907828 with BI 754091 (ezabenlimab) followed by expansion cohorts, in patients with advanced solid tumors
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 170
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Provision of signed and dated, written informed consent form ICF in accordance with ICH-GCP and local legislation prior to any trial-specific procedures, sampling, or analyses.
- •2. ECOG performance status of 0 or 1.
- •3. Patient must be willing to submit to the blood sampling for the PK, PD, and tumor mutation analysis
排除标准
- •1. Patients who have been treated with any other anticancer drug other than antibodies within 4 weeks or within 5 half-life periods (whichever come earlier) prior to first administration of trial medication.
- •2. Persistent toxicity from previous treatments that has not resolved to CTCAE Grade 1.
- •3. Any other documented active or suspected malignancy or history of malignancy within 3 years prior to screening.
研究者
相似试验
尚未招募
不适用
A phase Ia/Ib, open label, dose-escalation study of the combination of BI 907828 with BI 754091 (ezabenlimab) and BI 754111 and the combination of BI 907828 with BI 754091 (ezabenlimab) followed by expansion cohorts, in patients with advanced solid tumorsCancer (solid tumors)10027476NL-OMON53927Boehringer Ingelheim4
招募中
1 期
A phase I study of ROSE12 alone and in combination with other anti-tumor agents in patients with solid tumorssolid tumorJPRN-jRCT2031230072Ajari Ifode219
招募中
不适用
A Phase Ia/Ib Open Label, Dose-Escalation study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Tumors.NL-OMON55424Hoffmann-La Roche28
进行中（未招募）
1 期
Safety, immunogenicity and preliminary clinical activity study of PDC*lung01 cancer vaccine in NSCLCon-small-cell lung cancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-002382-19-PLPDC*line Pharma SAS64
进行中（未招募）
1 期
Safety, immunogenicity and preliminary clinical activity study of PDC*lung01 cancer vaccine in NSCLCon-small-cell lung cancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-002382-19-DEPDC*line Pharma SAS64